Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Finasteride Use and Risk … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Finasteride Use and Risk of Male Breast Cancer: A Case-Control Study Using Individual-Level Registry Data from Denmark, Finland, and Sweden

Artikel i vetenskaplig tidskrift
Författare T. M. Kjaerulff
A. K. Ersboll
A. Green
M. Emneus
K. Brasso
P. Iversen
E. Pukkala
Kristian Bolin
L. C. Thygesen
Publicerad i Cancer Epidemiology Biomarkers & Prevention
Volym 28
Nummer/häfte 5
Sidor 980-986
ISSN 1055-9965
Publiceringsår 2019
Publicerad vid Centrum för hälsoekonomi (CHEGU)
Institutionen för nationalekonomi med statistik
Sidor 980-986
Språk en
Länkar dx.doi.org/10.1158/1055-9965.Epi-18...
Ämnesord 5-alpha reductase inhibitors, benign prostatic hyperplasia, 5-alpha-reductase inhibitors, nordic countries, resource, cohort, Oncology, Public, Environmental & Occupational Health
Ämneskategorier Cancer och onkologi

Sammanfattning

Background: In case reports, concerns have been raised as to whether finasteride use increases the risk of male breast cancer. Previous epidemiologic evidence on the potential link is conflicting. This study aimed to assess whether an association between finasteride use and male breast cancer exists after accounting for potential confounders. Methods: The source population consisted of all men (similar to 35 years) from Denmark (1995-2014), Finland (1997-2013), and Sweden (2005-2014). Cases with incident male breast cancer were identified in the cancer registries and matched with 50 density-sampled, age, and country-matched male population controls per case. Exposure information on finasteride use was derived from the prescription registries. Potential confounders were identified using the directed acyclic graph methodology and measured by use of information from nation-wide registries. Results: The study population comprised 1,005 male breast cancer cases and 43,058 controls. Confounder-adjusted odds of finasteride exposure were not statistically significantly increased [OR, 1.09; 95% confidence interval (CI), 0.77-1.54] in breast cancer cases relative to controls. There was no evidence of a dose-response relationship, as the group with greatest exposure to finasteride was associated with lowest OR of male breast cancer [OR, 0.72 (95% CI, 0.40-1.30)]. Sensitivity analyses did not reveal marked changes in results with different exposure definitions or for specific subgroups. Conclusions: Results from this study provided no evidence that finasteride use was associated with male breast cancer. Impact: This large confounder-adjusted study supports the view that exposure to finasteride is not associated materially with male breast cancer risk.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?